| Global dialysis perspective: India J Bharati, V Jha Kidney360 1 (10), 1143-1147, 2020 | 53 | 2020 |
| Persistent CD‐19 depletion by rituximab is cost‐effective in maintaining remission in calcineurin‐inhibitor dependent podocytopathy R Ramachandran, J Bharati, I Rao, AW Kashif, R Nada, R Minz, KL Gupta, ... Nephrology 24 (12), 1241-1247, 2019 | 20 | 2019 |
| The Global Kidney Health Atlas: Burden and Opportunities to Improve Kidney Health Worldwide. J Bharati, V Jha, A Levin Annals of Nutrition & Metabolism 76, 2020 | 12 | 2020 |
| Global kidney health atlas: a spotlight on the Asia-Pacific sector J Bharati, V Jha Kidney Research and Clinical Practice 41 (1), 22, 2022 | 11 | 2022 |
| Long-term follow-up of cyclical cyclophosphamide and steroids versus tacrolimus and steroids in primary membranous nephropathy R Ramachandran, V Kumar, J Bharati, B Rovin, R Nada, V Kumar, ... Kidney International Reports 6 (10), 2653-2660, 2021 | 10 | 2021 |
| Atypical anti-GBM disease J Bharati, Y Yang, P Sharma, KD Jhaveri Kidney International Reports, 2023 | 9 | 2023 |
| AA amyloidosis associated with cancers J Bharati, OB Lahoud, KD Jhaveri, H Izzedine Nephrology Dialysis Transplantation 38 (6), 1366-1374, 2023 | 8 | 2023 |
| Addison's disease due to histoplasmosis of bilateral adrenal glands in a previously treated extrapulmonary tuberculosis case SK Sharma, M Tripathi Indian Journal of Medical Research 152 (Suppl 1), S1-S3, 2020 | 8 | 2020 |
| Achieving dialysis adequacy: A global perspective J Bharati, V Jha Seminars in Dialysis 33 (6), 490-498, 2020 | 8 | 2020 |
| Comparison of two steroid regimens in induction therapy of proliferative lupus nephritis: a randomized controlled trial J Bharati, M Rathi, R Ramachandran, A Sharma, V Kumar, HS Kohli, ... Indian journal of nephrology 29 (5), 373-375, 2019 | 7 | 2019 |
| The environment and kidney health: challenges and opportunities. J Bharati, C Zavaleta-Cortijo, T Bressan, A Shingada, G Obrador, L Sola, ... salud pública de méxico 64, S46-S55, 2022 | 6 | 2022 |
| COVID‐19 pandemic in limited‐resource countries: Strategies for challenges in a dialysis unit J Bharati, R Ramachandran, V Kumar, HS Kohli Nephrology (Carlton, Vic.) 25 (10), 803, 2020 | 6 | 2020 |
| Rituximab in maintaining remission in adults with podocytopathy R Ramachandran, J Bharati, R Nada, R Minz, HS Kohli Nephrology 25 (8), 616-624, 2020 | 6 | 2020 |
| Utility of plasma exchange in early recurrent C3 glomerulopathy A Kumar, J Bharati, R Nada, S Singh, A Sharma, KL Gupta, ... Indian Journal of Transplantation 13 (2), 122-126, 2019 | 6 | 2019 |
| Successful treatment of C1q nephropathy with CD19 targeted Rituximab therapy. R Ramachandran, J Bharati, V Jha Nephrology 22 (3), 2017 | 6 | 2017 |
| Contribution of clinically indicated repeat renal biopsy in Indian patients with lupus nephritis KL Gupta, J Bharati, H Anakutti, N Pattanashetti, M Rathi, ... Indian Journal of Nephrology 30 (6), 377-381, 2020 | 5 | 2020 |
| Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy J Bharati, K Tiewsoh, A Kumar, R Nada, M Rathi, KL Gupta, HS Kohli, ... Clinical kidney journal 12 (4), 483-487, 2019 | 5 | 2019 |
| C-Terminal fibroblast growth factor-23 levels in non-nutritional hypophosphatemic rickets J Bharati, D Bhatia, P Khandelwal, N Gupta, A Sinha, R Khadgawat, ... The Indian Journal of Pediatrics 86, 555-557, 2019 | 4 | 2019 |
| Membranous nephropathy with light chain restricted deposits R Ramachandran, N Inamdar, J Bharati, AK Yadav, A Kumar, G Prakash, ... Nephrology 23 (8), 791-796, 2018 | 4 | 2018 |
| Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease S Nayak, V Rathore, J Bharati, KK Sahu Expert Review of Clinical Pharmacology 14 (12), 1513-1526, 2021 | 3 | 2021 |
Raja RamachandranAssociate Professor, Postgraduate Institute of Medical Education and Research, ChandigarhVerified email at pgimer.edu.in
